Autolus Therapeutics (AUTL) Competitors $2.37 +0.02 (+0.85%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$2.37 0.00 (0.00%) As of 07/3/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, NAMS, DNLI, and RXRXShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Its Competitors Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma Denali Therapeutics Recursion Pharmaceuticals Autolus Therapeutics (NASDAQ:AUTL) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has more risk & volatility, AUTL or BHC? Autolus Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Is AUTL or BHC more profitable? Autolus Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -0.41%. Autolus Therapeutics' return on equity of -52.82% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -52.82% -29.67% Bausch Health Cos -0.41%-540.45%5.26% Do analysts recommend AUTL or BHC? Autolus Therapeutics presently has a consensus price target of $9.32, suggesting a potential upside of 293.25%. Bausch Health Cos has a consensus price target of $7.42, suggesting a potential upside of 6.73%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Autolus Therapeutics is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Bausch Health Cos 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Which has preferable earnings and valuation, AUTL or BHC? Bausch Health Cos has higher revenue and earnings than Autolus Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.12M62.33-$220.66M-$0.88-2.69Bausch Health Cos$9.63B0.27-$46M-$0.11-63.17 Do institutionals & insiders have more ownership in AUTL or BHC? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 8.1% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor AUTL or BHC? In the previous week, Autolus Therapeutics and Autolus Therapeutics both had 4 articles in the media. Bausch Health Cos' average media sentiment score of 0.51 beat Autolus Therapeutics' score of 0.28 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch Health Cos 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAutolus Therapeutics beats Bausch Health Cos on 9 of the 15 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$630.76M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-2.6921.5627.5220.22Price / Sales62.33281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book1.477.518.045.67Net Income-$220.66M-$55.05M$3.18B$249.13M7 Day Performance2.60%4.61%2.90%3.28%1 Month Performance4.87%4.72%3.70%5.55%1 Year Performance-31.30%5.92%36.15%21.12% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.5531 of 5 stars$2.37+0.9%$9.32+293.2%-32.1%$630.76M$10.12M-2.69330BHCBausch Health Cos3.1352 of 5 stars$6.11-1.1%$7.42+21.4%-2.8%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+23.2%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.4456 of 5 stars$17.62-0.4%$40.05+127.3%-49.2%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9959 of 5 stars$15.51+1.2%$43.71+181.8%-33.1%$2.14B$3.55M-11.08400Positive NewsTWSTTwist Bioscience4.4751 of 5 stars$35.33+2.0%$50.40+42.7%-20.6%$2.12B$347.68M-10.87990VCELVericel2.9188 of 5 stars$41.80-0.5%$61.14+46.3%-7.0%$2.10B$237.22M1,393.80300Positive NewsKNSAKiniksa Pharmaceuticals International3.5302 of 5 stars$28.72+1.0%$38.80+35.1%+45.8%$2.10B$423.24M-114.88220NAMSNewAmsterdam Pharma3.1136 of 5 stars$18.21+1.4%$42.89+135.5%-0.8%$2.04B$45.56M-9.694DNLIDenali Therapeutics4.6336 of 5 stars$13.62-1.9%$33.71+147.5%-31.0%$1.98B$330.53M-5.10430Positive NewsRXRXRecursion Pharmaceuticals2.1072 of 5 stars$4.83-4.0%$7.00+44.9%-28.4%$1.96B$58.84M-2.73400Analyst Forecast Related Companies and Tools Related Companies Bausch Health Cos Competitors Gemini Therapeutics Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Vericel Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Denali Therapeutics Competitors Recursion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts